Site consolidation: Meridian boosts US footprint in response to demand for ‘expanded relationships’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: Meridian Clinical Research, Regional Clinical Research, Clinical trial site, CRO, Vaccines, Infectious diseases, Neurology, Women's health

Meridian Clinical Research acquires Regional Clinical Research in a deal that will see its North American footprint expand to more than 20 investigative clinical trial sites.

Omaha, NE-based Meridian Clinical Research is strategically aligned with seven top-10 sponsors and eight of the top-10 contract research organizations (CROs), according to the company, which supports more than 60 principal investigators.

Members of the broader clinical trial site network, Platinum Research Network, Meridian and Regional Clinical Research have collaborated in the past.

Regional was established in 1993 and operates four research sites in New York and has 10 principal investigators.

Meridian CEO, Nicole Osborn, said the acquisition is a response to growing client demands for expanded relationships.

“The acquisition reinforces therapeutic depth in key areas — including vaccines/infectious diseases, neurology, and women’s health — while giving Meridian a way to expand operations in a sustainable way,”​ she told us.

“Clients and partners can expect business as usual, with enhanced service offerings coming soon,” ​Osborn added. “Together, Meridian and Regional will combine resources and therapeutic depth to provide richer clinical research capabilities and greater access to patients.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars